Dimpal Nyayanit
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dimpal Nyayanit has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Pragya Dhruv Yadav
ICMR-National Institute of Virology, Pune, India
6 shared publications - Gajanand N Sapkal
Diagnostic Virology Group, National Institute of Virology, Pune, India
5 shared publications - Anita M. Shete
ICMR - National Institute of Virology, Pune, India
4 shared publications - Nivedita Gupta
Indian Council of Medical Research
4 shared publications - Rima R. Sahay
Indian Council of Medical Research-National Institute of Virology, Pune, India
4 shared publications - Balram Bhargava
Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India
3 shared publications
Latest Publications
- Open Access
Protective Immunity of the Primary SARS-CoV-2 Infection Reduces Disease Severity Post Re-Infection with Delta Variants in Syrian Hamsters
The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Delta variant has evolved to become the dominant SARS-CoV-2 lineage with multiple sub-lineages and there are also reports of re-infections caused by this variant. We studied the disease characteristics induced by the Delta AY.1 variant and compared it with the Delta and B.1 variants in Syrian hamsters. We also assessed the potential of re-infection by these variants in Coronavirus disease 2019 recovered hamsters 3 months after initial infection. The variants produced disease characterized by high viral load in the respiratory tract and interstitial pneumonia. The Delta AY.1 variant produced mild disease in the hamster model and did not show any evidence of neutralization resistance due to the presence of the K417N mutation, as speculated. Re-infection with a high virus dose of the Delta and B.1 variants 3 months after B.1 variant infection resulted in reduced virus shedding, disease severity and increased neutralizing antibody levels in the re-infected hamsters. The reduction in viral load and lung disease after re-infection with the Delta AY.1 variant was not marked. Upper respiratory tract viral RNA loads remained similar after re-infection in all the groups. The present findings show that prior infection could not produce sterilizing immunity but that it can broaden the neutralizing response and reduce disease severity in case of reinfection.
Open AccessProtective Immunity of the Primary SARS-CoV-2 Infection Reduces Disease Severity Post Re-Infection with Delta Variants in Syrian Hamsters
The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Delta variant has evolved to become the dominant SARS-CoV-2 lineage with multiple sub-lineages and there are also reports of re-infections caused by this variant. We studied the disease characteristics induced by the Delta AY.1 variant and compared it with the Delta and B.1 variants in Syrian hamsters. We also assessed the potential of re-infection by these variants in Coronavirus disease 2019 recovered hamsters 3 months after initial infection. The variants produced disease characterized by high viral load in the respiratory tract and interstitial pneumonia. The Delta AY.1 variant produced mild disease in the hamster model and did not show any evidence of neutralization resistance due to the presence of the K417N mutation, as speculated. Re-infection with a high virus dose of the Delta and B.1 variants 3 months after B.1 variant infection resulted in reduced virus shedding, disease severity and increased neutralizing antibody levels in the re-infected hamsters. The reduction in viral load and lung disease after re-infection with the Delta AY.1 variant was not marked. Upper respiratory tract viral RNA loads remained similar after re-infection in all the groups. The present findings show that prior infection could not produce sterilizing immunity but that it can broaden the neutralizing response and reduce disease severity in case of reinfection.
- Open Access
- 4 March 2022
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 29 (3)
Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine
Within a short span of time severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines developed through usage of different platforms have been approved across the globe. Such vaccines have acted as disease modifying tools by reducing the severity of the clinical course of infection and mortality due to coronavirus disease 2019 (COVID-19). However, the recent emergence of SARS-CoV-2 variant of concern (VOC) Omicron with its high transmissibility, has led to rapid surge in the number of COVID-19 cases including the breakthroughs and re-infections. 1 Against this background, marked immune escape potential of the Omicron variant has been at the centre stage of discussion. There has also been growing interest in mix and match booster vaccination against COVID-19 across the globe in the light of newly emerging VOCs and many countries have started following the heterologous booster vaccination approach. 2 Preliminary studies have reported the safety, and improved humoral and cellular immune responses with a heterologous boost approach than a homologous one. 2
- 4 March 2022
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 29 (3)
Open AccessImmune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine
Within a short span of time severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines developed through usage of different platforms have been approved across the globe. Such vaccines have acted as disease modifying tools by reducing the severity of the clinical course of infection and mortality due to coronavirus disease 2019 (COVID-19). However, the recent emergence of SARS-CoV-2 variant of concern (VOC) Omicron with its high transmissibility, has led to rapid surge in the number of COVID-19 cases including the breakthroughs and re-infections. 1 Against this background, marked immune escape potential of the Omicron variant has been at the centre stage of discussion. There has also been growing interest in mix and match booster vaccination against COVID-19 across the globe in the light of newly emerging VOCs and many countries have started following the heterologous booster vaccination approach. 2 Preliminary studies have reported the safety, and improved humoral and cellular immune responses with a heterologous boost approach than a homologous one. 2
- Open Access
- 15 October 2021
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 28 (8)
Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin
COVID-19 vaccination program was rolled out in India on January 16th 2021. 1 The whole virion inactivated BBV152 (Covaxin) and AstraZeneca’s ChAdOx1-nCov-19 (Covishield) were the two vaccines initially included under this program. 2, 3, 4, 5 Frontline workers including healthcare professionals, elderly above the age of 60 and adults with co-morbidity were prioritized for vaccination before reaching out to all the adults. During expansion of the aforementioned vaccination program, a group of participants in the northern state of Uttar Pradesh received Covishield (CS) as the first dose followed by inadvertent administration of Covaxin (CV) as the second dose. We studied the safety and immunogenicity of this heterologous prime-boost COVID-19 vaccination. A total of 98 vaccine recipients who had completed two weeks or more after the second dose of vaccine were included in this study. Three groups of participants were recruited during May to June 2021: heterologous group (n = 18, first dose CS, second dose CV administered at an interval of six weeks), among them, 11 were male (M/F:11/7) with a median age of 62 year (IQR 54.25–69.75). A comorbid condition (hypertension) was reported in one participant. Homologous CS group (n = 40, 22 were males and the rest were female (M/F:22/18) with a median age of 65.5 years (IQR 62–69) and co-morbidity was observed among 4 participants who received two CS-vaccine doses at six weeks interval. The homologous CV-group (n = 40, two vaccine doses administered at four weeks interval including 23 females (M/F:17/23) with a median age of 56 year (IQR 45.5–63) and 3 with co-morbidities ( Supplementary Table 1 ) ( Supplementary Figure S1 ).
- 15 October 2021
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 28 (8)
Open AccessImmunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin
COVID-19 vaccination program was rolled out in India on January 16th 2021. 1 The whole virion inactivated BBV152 (Covaxin) and AstraZeneca’s ChAdOx1-nCov-19 (Covishield) were the two vaccines initially included under this program. 2, 3, 4, 5 Frontline workers including healthcare professionals, elderly above the age of 60 and adults with co-morbidity were prioritized for vaccination before reaching out to all the adults. During expansion of the aforementioned vaccination program, a group of participants in the northern state of Uttar Pradesh received Covishield (CS) as the first dose followed by inadvertent administration of Covaxin (CV) as the second dose. We studied the safety and immunogenicity of this heterologous prime-boost COVID-19 vaccination. A total of 98 vaccine recipients who had completed two weeks or more after the second dose of vaccine were included in this study. Three groups of participants were recruited during May to June 2021: heterologous group (n = 18, first dose CS, second dose CV administered at an interval of six weeks), among them, 11 were male (M/F:11/7) with a median age of 62 year (IQR 54.25–69.75). A comorbid condition (hypertension) was reported in one participant. Homologous CS group (n = 40, 22 were males and the rest were female (M/F:22/18) with a median age of 65.5 years (IQR 62–69) and co-morbidity was observed among 4 participants who received two CS-vaccine doses at six weeks interval. The homologous CV-group (n = 40, two vaccine doses administered at four weeks interval including 23 females (M/F:17/23) with a median age of 56 year (IQR 45.5–63) and 3 with co-morbidities ( Supplementary Table 1 ) ( Supplementary Figure S1 ).
- Open Access
- 28 September 2021
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 28 (8)
Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Delta variant (B.1.617.2), a variant of concern, was associated with the second wave of pandemic in India during March–May 2021. Delta variant has outpaced the other two sub-lineages Kappa (B.1.617.1) and B.1.617.3 and was responsible for 90% of the cases reported in India. 1 It has spread across 112 countries and found to be more infectious than the Alpha, Beta and Gamma variants. Reduced neutralization has been reported with the sera of individuals vaccinated with BNT162b2, BBV152/Covaxin and chAdOx1-s against Delta variant in recent reports. 2, 3 Delta variant has also been identified as the leading cause of breakthrough infections globally among vaccinated individuals. 4
- 28 September 2021
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 28 (8)
Open AccessComparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Delta variant (B.1.617.2), a variant of concern, was associated with the second wave of pandemic in India during March–May 2021. Delta variant has outpaced the other two sub-lineages Kappa (B.1.617.1) and B.1.617.3 and was responsible for 90% of the cases reported in India. 1 It has spread across 112 countries and found to be more infectious than the Alpha, Beta and Gamma variants. Reduced neutralization has been reported with the sera of individuals vaccinated with BNT162b2, BBV152/Covaxin and chAdOx1-s against Delta variant in recent reports. 2, 3 Delta variant has also been identified as the leading cause of breakthrough infections globally among vaccinated individuals. 4
- Open Access
SARS-CoV-2 Delta Variant Pathogenesis and Host Response in Syrian Hamsters
B.1.617 is becoming a dominant Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) lineage worldwide with many sublineages, of which B.1.617.2 is designated as a variant of concern. The pathogenicity of B.1.617.2 (Delta) and B.1.617.3 lineage of SARS-CoV-2 was evaluated and compared with that of B.1, an early virus isolate with D614G mutation in a Syrian hamster model. Viral load, antibody response, and lung disease were studied. There was no significant difference in the virus shedding pattern among these variants. High levels of SARS-CoV-2 sub genomic RNA were detected in the respiratory tract of hamsters infected with the Delta variant for 14 days, which warrants further transmission studies. The Delta variant induced lung disease of moderate severity in about 40% of infected animals, which supports the attributed disease severity of the variant. Cross neutralizing antibodies were detected in animals infected with B.1, Delta, and B.1.617.3 variant, but neutralizing capacity was significantly lower with B.1.351 (Beta variant).
Open AccessSARS-CoV-2 Delta Variant Pathogenesis and Host Response in Syrian Hamsters
B.1.617 is becoming a dominant Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) lineage worldwide with many sublineages, of which B.1.617.2 is designated as a variant of concern. The pathogenicity of B.1.617.2 (Delta) and B.1.617.3 lineage of SARS-CoV-2 was evaluated and compared with that of B.1, an early virus isolate with D614G mutation in a Syrian hamster model. Viral load, antibody response, and lung disease were studied. There was no significant difference in the virus shedding pattern among these variants. High levels of SARS-CoV-2 sub genomic RNA were detected in the respiratory tract of hamsters infected with the Delta variant for 14 days, which warrants further transmission studies. The Delta variant induced lung disease of moderate severity in about 40% of infected animals, which supports the attributed disease severity of the variant. Cross neutralizing antibodies were detected in animals infected with B.1, Delta, and B.1.617.3 variant, but neutralizing capacity was significantly lower with B.1.351 (Beta variant).
- Open Access
- 28 January 2021
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 28 (2)
Isolation and characterization of the new SARS-CoV-2 variant in travellers from the United Kingdom to India: VUI-202012/01 of the B.1.1.7 lineage
Since its emergence in China during December 2019, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has marked its presence all across the globe. During this pandemic phase, the new genetic mutations acquired by the virus have led to new variants, indicating that the virus is evolving. This is indicated by the emergence of two SARS-CoV-2 variants, B.1.1.7 lineage (a.k.a. 20B/501Y.V1 variant of concern [VOC] 202012/01) and B.1.351 lineage (a.k.a. 20C/501Y.V2) identified from UK and South Africa, respectively. The B.1.1.7 lineage has eight mutations in Spike receptor-binding domain which mediates the attachment of the virus to the angiotensin-converting enzyme 2 receptor on the surface of human cells, whereas the B.1.351lineage has the N501Y but not the 69/70 deletion. 1, 2 B.1.1.7 lineage phenotype has also attracted attention, as it proves to be much more transmissible among humans than the other known SARS-CoV-2 lineages. 1, 2 The genetic mutations in these new variants are associated with rapid transmission of the infection. 3 However, its effect on the severity of the disease and vaccine efficacy has not yet studied.
- 28 January 2021
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 28 (2)
Open AccessIsolation and characterization of the new SARS-CoV-2 variant in travellers from the United Kingdom to India: VUI-202012/01 of the B.1.1.7 lineage
Since its emergence in China during December 2019, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has marked its presence all across the globe. During this pandemic phase, the new genetic mutations acquired by the virus have led to new variants, indicating that the virus is evolving. This is indicated by the emergence of two SARS-CoV-2 variants, B.1.1.7 lineage (a.k.a. 20B/501Y.V1 variant of concern [VOC] 202012/01) and B.1.351 lineage (a.k.a. 20C/501Y.V2) identified from UK and South Africa, respectively. The B.1.1.7 lineage has eight mutations in Spike receptor-binding domain which mediates the attachment of the virus to the angiotensin-converting enzyme 2 receptor on the surface of human cells, whereas the B.1.351lineage has the N501Y but not the 69/70 deletion. 1, 2 B.1.1.7 lineage phenotype has also attracted attention, as it proves to be much more transmissible among humans than the other known SARS-CoV-2 lineages. 1, 2 The genetic mutations in these new variants are associated with rapid transmission of the infection. 3 However, its effect on the severity of the disease and vaccine efficacy has not yet studied.